New Antibiotics for Community-Acquired Pneumonia

Marin H. Kollef; Kevin D. Betthauser


Curr Opin Infect Dis. 2019;32(2):169-175. 

In This Article


CAP continues to be an important infection because of its impact on patient outcomes especially in the elderly and immunocompromised hosts. The availability of new antibiotics offers an opportunity for enhanced empiric treatment of antibiotic-resistant bacterial pathogens associated with CAP. However, we need to insure that these new antibiotics are effective and well tolerated in patients, and that their use is appropriate to avoid emergence of resistance. We also need to continue to develop new antibiotics for the treatment of CAP as well as nontraditional agents, such as monoclonal antibodies, vaccines, and small molecules that will further minimize or avoid the emergence of antimicrobial resistance.